Melanoma & Skin Cancer Articles

Adjuvant Pembrolizumab Improves RFS in Melanoma
Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.
FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF+ Melanoma
The FDA has granted a priority review to a supplemental new drug application for the use of dabrafenib combined with trametinib as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.
 
FDA Approves Adjuvant Nivolumab for Melanoma
The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Immunotherapy Resistance Remains a Puzzle
Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.
Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.
Standard Adjuvant Therapy for Melanoma Within Reach
Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.
Combination Therapies Push Melanoma Field Forward
Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.
Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets
Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.
Ipilimumab Effective in Adolescents With Advanced Melanoma
Ipilimumab was associated with a 1-year overall survival rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.
Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma
Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.
Publication Bottom Border
Border Publication
x